TLV •
Healthcare •
Biotechnology •
Quote as of 09/08/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeTLV
Market Capitalization19.66 mln
Float601 mln
Earnings Date07/31/2026
Piotroski F-Score
2
/ 9
Weak
Relative Strength
4
/ 100
Severely lagging
Debt / Equity
-1.06
Negative equity
ROE
-407
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
Founded in 1993 and based in Ramat Gan, Israel, XTL Biopharmaceuticals focuses on finding and advancing treatments for autoimmune conditions. Its most advanced product, hCDR1, is prepared to enter Phase II clinical trials and targets diseases such as lupus and Sjogren's syndrome. The company holds a licensing agreement with Yeda Research and Development to support the ongoing study and future commercialization of hCDR1.
